Opicapone for the treatment of Parkinson's disease: real-life data in Spain
N López-Ariztegui 1 , M Mata-Alvarez Santullano 2 3 , I Tegel 4 , F Almeida 4 , P Sarasa 4 , R Rojo 5 , F Rico-Villademoros 6 7 , J Abril-Jaramillo 8 , P Bermejo 9 , C Borrue 3 , N Caballol 10 , M Campins-Romeu 11 , P Clavero 12 , J García-Caldentey 13 , V Gómez-Mayordomo 14 , C Labandeira 15 , G Martí-Andrés 16 , J C Martínez-Castrillo 17 , J Martinez-Poles 18 , T Muñoz 19 , J M Salom 20 , C Valderrama-Martín 21 , A Vinagre-Aragón 22
Opicapone is a catechol-O-methyl-transferase (iCOMT) inhibitor authorized in Europe in 2016 and indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
The efficacy of opicapone in these patients has been demonstrated in two pivotal randomized clinical trials, BIPARK I and BIPARK II, in which it has demonstrated its superiority versus placebo and non-inferiority versus entacapone.
Although they constitute the gold standard for the evaluation of interventions, randomized clinical trials present limitations of external validity due to the use of strict eligibility criteria.
Therefore, it is considered necessary to have a more comprehensive evaluation of the efficacy of the drug, complementing the information obtained from randomized clinical trials with that of "real world or real clinical practice" studies.
The objective of this review has been to collect and put into perspective the information available on opicapone coming from real clinical practice studies in Spain. The data from Spain with opicapone in 18 series with more than 1,000 patients in total, confirm the safety and efficacy previously reported with this iCOMT.
Furthermore, they show that opicapone is especially useful in patients with a less advanced stage of the disease and mild motor fluctuations, which would suggest that the earlier its introduction in the therapeutic scheme for the management of motor fluctuations, the better is the benefit-risk ratio for the drug.
CITATION Rev Neurol. 2021 Dec 24;73(s02):S01-S14. doi: 10.33588/rn.73s02.2021461